A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
A phase 2 trial of Durvalumab, Tremelimumab, Pemetrexed, Pembrolizumab, Carboplatin and Cisplatin in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
Overview
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS is a phase 2 interventional study registered as NCT06008093 by AstraZeneca, with 103 participants enrolled, started 2024-04-04 and due to reach its primary completion in 2026-10-23. Interventions recorded: Durvalumab, Tremelimumab, Pemetrexed, Pembrolizumab, Carboplatin and Cisplatin.
Similar pages
not linked directly; found by shared links- TrialPhase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
Shares Pemetrexed, Durvalumab, Cisplatin, AstraZeneca and the tag pipeline.
- TrialPhase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
Shares Tremelimumab, Durvalumab, Cisplatin, AstraZeneca and the tag pipeline.
- TrialStudy of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
Shares Tremelimumab, Durvalumab, Cisplatin, AstraZeneca and the tag pipeline.
- TrialStudy of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
Shares Tremelimumab, Durvalumab, Cisplatin, AstraZeneca and the tag pipeline.
- TrialStudy of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
Shares Tremelimumab, Durvalumab, Cisplatin, AstraZeneca and the tag pipeline.
- TrialStudy of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
Shares Pemetrexed, Durvalumab, Cisplatin, AstraZeneca and the tag pipeline.
- TrialSavolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
Shares Pemetrexed, Cisplatin, AstraZeneca, Carboplatin and the tag pipeline.
- TrialCombination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.